Getting into adolescent heads: An essential update

Food Insecurity and the Dangers of Infant Formula Dilution

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

January 30th 2023

Bavarian Nordic initiates trial of chikungunya vaccine in children aged 2-11 years

Demystifying Infant Formula

Currently, Vimkunya is FDA-approved for use among individuals aged 12 years and older.

October 11th 2022

Michael Daines, MD, discusses pediatric acute-onset neuropsychiatric syndrome

Michael O. Daines, MD

FDA expands glecaprevir/pibrentasvir indication for acute hepatitis C down to 3 years of age

Michael O. Daines, MD, outlines key diagnostic criteria and treatment challenges for pediatric acute-onset neuropsychiatric syndrome (PANS), emphasizing the need for multidisciplinary care and improved treatment access.

Weekly review: Clesrovimab for RSV approved, new dupilumab data, and more

Glecaprevir/pibrentasvir was a "highly efficacious treatment for people with acute HCV," with 96.2% of patients analyzed having sustained virological response 12 weeks post-treatment.

Related Content

Food Insecurity and the Dangers of Infant Formula Dilution

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

January 30th 2023

Bavarian Nordic initiates trial of chikungunya vaccine in children aged 2-11 years

Demystifying Infant Formula

Currently, Vimkunya is FDA-approved for use among individuals aged 12 years and older.

October 11th 2022

Michael Daines, MD, discusses pediatric acute-onset neuropsychiatric syndrome

Michael O. Daines, MD

FDA expands glecaprevir/pibrentasvir indication for acute hepatitis C down to 3 years of age